M
ULTIPLE SCLEROSIS (MS) IS believed to involve a complex interplay between environmental triggers (such as infections), genetic predisposition, and aberrant immune cell activation. Epidemiological studies suggest that environmental exposure to a putative infectious agent must occur during a specific window of immunological vulnerability in childhood. 1 Epstein-Barr Virus (EBV) is of particular interest. Acute symptomatic infection with EBV (infectious mononucleosis) can be associated with central nervous system (CNS) demyelination. 2 Although the majority of adult MS patients do not have clinical or serological evidence of acute mononucleosis at the time of MS diagnosis, nearly 100% demonstrate serological evidence of remote EBV infection. 1, 3, 4 While the association of EBV with adult MS is statistically significant, the pathobiological significance of this observation has been questioned since EBV infects more than 90% of the healthy adult population of Western societies. 5 Infection with EBV occurs in childhood or adolescence in 50% of individuals 6 ; the remainder contract EBV during early adulthood. Approximately 5% of all MS patients experience the onset of their disease prior to age 18 years. 7, 8 If EBV infection is involved in the initiation of MS, children with MS should demonstrate serological evidence of prior EBV exposure at the time of their MS diagnosis, at an age when the majority of their healthy peers have yet to be exposed to the virus.
METHODS

Participants
Epstein-Barr virus serological studies were available for 30 of 35 children with clinically definite MS (defined by 2 separate and well-documented demyelinating attacks 9 ) enrolled in the Pediatric MS Clinic at the Hospital for Sick Children (Toronto, Ontario) as of February 2003. Viral samples were collected from March 1994 to February 2003. Viral serology was not available for 4 children referred from outside Canada and for 1 child in whom initial viral results were inconclusive and archived serum was insufficient for reanalysis. Selection of control samples was based on the availability of EBV serological results and/or archived serum samples stored in the virology department. To study completely healthy children, we selected samples obtained from bone marrow transplant (BMT) donors. To control for age, we selected samples from an emergency department (ED) cohort matched 3:1 for age with each MS patient. Selection of control samples was performed by searching, using predetermined search strategies, the Hospital for Sick Children databases for patients entered between 1993 and the end of 2002. All searches were performed blinded to the viral serological results. For the BMT controls the following search criteria were applied: (1) listed as a BMT donor in the database; (2) age between 4 and 18 years; and (3) EBV serology performed. Medical charts were reviewed, and only those BMT donors documented to be completely healthy were then included. For the ED cohort, the following search criteria were used: (1) the patient had been seen in the ED with a presenting diagnosis of rash, pharyngitis, or abdominal pain, and (2) EBV serology was obtained. Medical charts of the potential ED controls were reviewed to ensure that the child was documented to be completely well prior to the acute illness that prompted the ED visit.
Detection of Antiviral Antibodies
Serum samples from all participants were analyzed in the licensed clinical microbiology laboratory at the Hospital for Sick Children in batches, blinded to case status. Samples were analyzed using standardized enzyme-linked immunosorbent assay (ELISA) kits for IgG antibodies directed against EBV capsid (EBV-VCA), nuclear (EBV-EBNA), and early antigens (EBV-EA) (DiaSorin, Stillwater, Minn). Archived samples from the MS cohort and ED controls, obtained and stored at the time of initial EBV sampling, were then retrieved and analyzed for the presence of IgG antibodies directed against cytomegalovirus (CMV) (Zeus Scientific, Raritan, NJ), parvovirus B19 (Biotrin International Ltd, Mount Merrion, Co. Dublin, Ireland), varicella zoster virus (VZV) (Zeus Scientific), and herpes simplex virus (HSV) (BioChem ImmunoSystems Italia SPA, Casalecchio di Reno, Italy). Twenty of the control samples originally analyzed for EBV using immunofluorescence assays were reanalyzed by ELISA to ensure uniform methodology. The HSV ELISA kit does not discriminate infection with HSV-I from HSV-2. One MS patient had insufficient serum to analyze for VZV, another insufficient serum for HSV, and a third patient had no archived serum available. The remaining 27 MS patients and 67 of the ED controls had sufficient archived serum for analysis of the entire viral panel.
Patients were classified as "remotely infected" if EBV antibodies against both VCA and EBNA (irrespective of EA) were detected, "recently infected" if antibodies against VCA and EA (but not EBNA) were detected, and "EBV-naive" if antibodies against all 3 EBV antigens were absent. Samples were viewed as uninterpretable if results did not conform to Barr virus−positive, non-Canadian-born MS patients is 81%, which does not differ from the MS cohort as a whole (83% Epstein-Barr virus positive). †Cerebrospinal fluid acquisition in children presenting with acute neurological deficits is typically performed by the primary care pediatrician to exclude infection, and often prior to confirmation of demyelination by magnetic resonance imaging. As a result, cerebrospinal fluid oligoclonal band studies are often not available. ‡Given the young age of the parents and first-degree relatives of pediatric MS patients, it is possible that some relatives will be diagnosed with MS in the future. §None of the children had received treatment with MS-targeted, disease-modifying therapies at the time of viral sample acquisition (interferons or glatiramer acetate). 
RESULTS
Subjects
The mean time from the first MS attack to viral sample acquisition was 1.36 years (TABLE 1). All MS children experienced multiple attacks, and although many are now receiving MStargeted therapies, none were receiving these treatments at the time of sample acquisition. None of the MS patients reported a history of symptoms compatible with acute mononucleosis. The mean age of the MS and matched ED cohorts was similar as expected (13.40 and 13.37 years, respectively), but the BMT patients were younger (10.30 years) (TABLE 2). There were more girls in the MS and ED cohorts but more boys in the BMT control group.
Antibodies Against EBV
As shown in FIGURE 1, remote EBV infection was identified in 83% of the MS cohort compared with 42% of the BMT controls (OR, 7.04; 95% CI, 2.3-21.3; PϽ.001) and 42% of the healthy, agematched ED controls (OR, 8.7; 95% CI, 2.5-30.3; PϽ.001). Only 17% of the MS patients were seronegative for EBV, compared with 55% of the BMT donor cohort (OR, 0.17; 95% CI, 0.06-0.5; PϽ.001) and 36% of the ED controls (OR, 0.27; 95% CI, 0.075-0.987; P = .04). As expected, recent infection was highest in the ED cohort (22%) in whom serological testing was performed due to clinically suspected acute EBV infection. Recent infection with EBV was not found in children with MS, even those sampled at the time of their first demyelinating episode.
Antibodies Against HSV, Parvovirus B19, VZV, and CMV
As shown in FIGURE 2, MS patients did not differ from controls for the prevalence of antibodies against parvovirus B19, VZV, or CMV, but were less likely to have been exposed to HSV than the control cohort (52% vs 88%) (OR, 0.14; 95% CI, 0.04-0.51; P=.003).
COMMENT
Pediatric MS patients are significantly more likely to have experienced EBV infection than their peers. Our results may be interpreted in several ways, including the following: (1) infection with EBV initiates or propagates MS pathogenesis; (2) MS leads to an increased susceptibility to B-cell infection with EBV; or (3) a common mechanism exists leading to heightened susceptibilities to early EBV infection and earlyonset MS.
The pathogenesis of MS may relate to immune responses to environmental agents such as viruses encountered during the pediatric-age window of risk. 5, [10] [11] [12] [13] [14] There are several features of EBV that make it biologically plausible that it could play a role in MS. Exposure to EBV results in persistent B-cell infection, expansion of EBVtransformed B-cell clones, and the production of antibodies directed against specific EBV viral antigens, as well as lifelong T-cell surveillance of infected B cells. 15 The presence of EBV antigenresponsive T cells is not inher- ently pathogenic, as they are present in a quiescent state in most healthy EBVpositive adults. The pathogenic potential of these T cells requires activation, possibly through molecular mimicry. A pentapeptide sequence found in the EBV nuclear antigen shares sequence homology with an epitope of myelin basic protein, a major component of the myelin sheath. 15 Furthermore, EBV induces B-cell surface expression of alpha-B crystallin, a protein recently identified as a major autoantigen constituent that is abnormally expressed in brains of patients with MS. 16 It is thus conceivable that exposure to EBV may lead to a misdirected host immune response against self-antigens in the CNS, such as alpha-B crystallin and/or myelin basic protein.
Epstein-Barr virus is not the only virus implicated in MS and clearly is not a requisite trigger, as evidenced by the 5 EBV-negative pediatric MS patients. A role for human herpesvirus 6 (HHV-6) has been suggested by studies of HHV-6 expression in CNS tissue and by the identification of increased HHV-6 antibody titers in serum samples of MS patients. 17 Human herpesvirus 6 variant A infection leads to activation of the EBV genome in EBV-positive B cells, 18 raising the possibility that multiple viral exposures may act in concert. However, the literature on HHV-6 is complicated by differences in methodology between studies, 19 and by the fact that nearly 100% of the population is infected with HHV-6 by the age of 2 years. Of greater interest would be the study of HHV-6 replicative/latency status, which would require molecular methods such as polymerase chain reaction techniques. 20 Such analyses are planned. Although many viral agents other than EBV, including Chlamydia pneumoniae, have been studied in MS, strong associations have yet to be documented, owing in part to differences in methodology and patient populations. 21 It is possible that the association between EBV infection and MS relates to increased exposure or susceptibility to EBV infection in MS-affected children, rather than a causal role for EBV in MS pathogenesis. However, pediatric MS patients do not seem to have an increased susceptibility or exposure to viruses in general, as evidenced by the similarity in seropositivity rates between MS patients and controls for parvovirus B19, CMV, and VZV.
Another important issue is whether EBV infection initiates, rather than propagates, the immunological processes involved in MS. A study of EBV infection in 3 million US military personnel demonstrated a strong positive association between EBV antibodies and MS risk in samples collected more than 5 years before MS diagnosis. 22 Further support for the role of EBV in the initiation of MS pathogenesis will be sought by studying EBV serology in children presenting with initial acute CNS demyelination: children subsequently diagnosed with MS would be expected to show evidence of remote EBV infection even at the time of their first attack.
An interesting observation in our study was the fact that healthy children were more likely than pediatric MS patients to be seropositive for HSV. Although our methodology does not allow discrimination between HSV-1 and HSV-2, most participants in our study were younger than 16 years and few were likely to be sexually active. Thus, their positive serological test results most probably reflect previous infection with HSV-1. It has been hypothesized that HSV-1 immunity is protective against MS. 23 If the sequence of viral exposures in childhood is important in MS pathobiology, then perhaps pediatric MS patients experience EBV infection without the "protective" benefit of early HSV-1 infection.
Although demographic data on our control cohorts are limited, it is unlikely that demographic differences between controls and MS patients would account for the marked difference in EBV seropositivity. In fact, the demographic features of our 2 control cohorts were not matched to each other, yet EBV seroprevalence was identical. Furthermore, the seroprevalence of EBV in our controls was similar to that of other pediatric control cohorts in North American studies of EBV. 6, 24 In addition, although the sample size of the current study was small, significant results were obtained. Validation of these results requires a larger, prospective study of multiple viruses in healthy children and pediatric MS patients. Role of the Sponsor: The Hospital for Sick Children Foundation had no involvement with the design or conduct of the study, with the interpretation of the data, or in the preparation, review, or approval of the manuscript. Children with multiple sclerosis were more likely to be positive for remote EBV infection than ED controls (*PϽ.001) and less likely to be HSV-positive ( †P=.003). There was no difference in seropositivity for parvovirus, VZV, or CMV between the multiple sclerosis and ED cohorts.
